Glaxo Wellcome, the UK’s fifth largest company, is to cut 1,700 jobs from its UK manufacturing operations in the next four years. The cuts follow a year-long manufacturing review and will mostly happen at the company’s site in Dartford, Kent.
Each Glaxo Wellcome site will now focus on a single product area. Secondary product manufacturing will end, leading to the 1,500 job losses at Dartford. The company believes reorganisation will create a simpler manufacturing structure.
The job cuts follow a tough period for the firm during which patent expiry has allowed competition for many of its biggest selling drugs, hitting profits.